相关实验视频
Updated: Jul 6, 2025

10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
10.0K
一个MYC重组是第二阶段的负预后因素,但不是第一阶段的扩散大B细胞淋巴瘤
A V de Jonge1,2, J A A Bult3, D F E Karssing4
1Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands. a.dejonge1@amsterdamumc.nl.
Blood cancer journal
|January 4, 2024
概括
在有限阶段的扩散性大B细胞淋巴瘤 (DLBCL) 中,MYC重组影响生存率. 患有MYC-R的II阶段DLBCL的结果较差,而I阶段DLBCL显示出不论MYC-R状态的生存率都很好.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 已知MYC瘤基因重组 (MYC-R) 对晚期扩散性大B细胞淋巴瘤 (DLBCL) 的存活率产生负面影响.
- 在有限阶段 (LS) DLBCL (Ann Arbor I-II阶段) 中MYC-R的预后意义仍然不清楚.
- 了解MYC-R在LS DLBCL中的作用对于完善诊断和治疗策略至关重要.
研究的目的:
- 评估MYC-R对限期DLBCL患者无进展生存期 (PFS) 和整体生存期 (OS) 的影响.
- 为了比较MYC-R阳性和阴性LS DLBCL患者之间的生存结果.
- 为了确定MYC-R状态是否会影响早期DLBCL的治疗决策.
主要方法:
- 使用荷兰癌症登记处进行的一项基于人口的研究确定了1434名在2014年至2020年期间被诊断为LS DLBCL患者.
- 患者接受了类似R-CHOP的化疗方案.
- 生存后续调查一直持续到2022年2月,分析了MYC-R状态,PFS和OS.
主要成果:
- 在I期DLBCL (n=733) 中,MYC-R状态没有显著影响2年的PFS (89%对比93%,p=0.63) 或OS (两者95%,p=0.22).
- 在II期DLBCL (n=701) 中,MYC-R与明显较差的结局相关:PFS为70%与89% (p=0.001) 相比,OS为79%与94% (p<0.0001) 相比,MYC-R阴性患者.
- 单击和双击/三击MYC-R变体都与II期DLBCL的死亡率和复发风险增加相关.
结论:
- MYC重组是第二阶段DLBCL生存的负预后因素.
- 在I期DLBCL中,无论MYC-R状态如何,生存结果都是有利的.
- 在I期DLBCL中对MYC-R的常规诊断评估可能需要重新评估,因为它缺乏预后影响.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Induced Pluripotent Stem Cells
4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.1K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K

